Safety profiles of novel agent therapies in CLL.
Safety profiles of novel agent therapies in CLL.
Hematology Am Soc Hematol Educ Program. 2017 Dec 08;2017(1):354-357
Authors: Ahn IE, Davids MS
Abstract
A 70-year-old man with relapsed/refractory chronic lymphocytic leukemia has multiple comorbidities including atrial fibrillation (on warfarin for anticoagulation), irritable bowel syndrome, and chronic renal insufficiency. Two years ago, he received bendamustine and rituximab as first-line therapy for chronic lymphocytic leukemia and achieved partial response, but now has relapsed. Fluorescence in situ hybridization cytogenetics reveals deletion 17p. Which novel agent would you recommend for this patient?
PMID: 29222278 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
More News: Atrial Fibrillation | Chronic Leukemia | Chronic Lymphocytic Leukemia | Coumadin | Education | Hematology | Irritable Bowel Syndrome | Leukemia | Rituxan | Treanda | Universities & Medical Training | Warfarin